tj101

Prostate Cancer

Phrontline BiopharmaPhase 1Active

C

36/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 59/ 100

Competitive context

513 Active assets in the Prostate Cancer cohort.

Asset / Sponsor	Phase	Rating
Avodart Bay State Clinical Trials, Inc.	Phase 4	BBB
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BBB
Degarelix Bayer	Phase 4	BBB
PROPOFOL Peter MacCallum Cancer Centre, Australia	Phase 4	BBB
AVOLVE Masonic Cancer Center, University of Minnesota	Phase 4	BB

View all 50 →

Same molecule, other indications

tj101 is also rated in:

non-small cell lung carcinomaDormant

CC

Indicative ·

41 / 100

Solid Tumor MalignanciesDormant

C

Indicative ·

39 / 100

esophageal cancerDormant

C

Indicative ·

37 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.